Basic Informations

C.V

Address: Ard El-Horia, Beni-Sueif,

Egypt.

 E-mail: shimaa_kottob@yahoo.com

Personal data:

      Date of birth: 23-8-1986

      Age:    28

      Gender: female

      Marital status: Married

      Religion: Moslem

      Nationality: Egyptian

      Current occupation: demonstrator in Medicinal chemistry        department, Faculty of pharmacy, Beni-suef University, Beni-suef, Egypt.

      Office address: Faculty of pharmacy, Beni-suef University, Egypt.

Education:

   *Bachelor of pharmaceutical sciences ( Excellent with honor)

     Faculty Of Pharmacy, Beni-Suef University , May2008.

  *Premaster degree (Excellent).

Certifications and Training courses:

 

Educational skills:  

Excellent Demonstrator of Medicinal Chemistry with 6 years experience (March 2009 up to now).

Computer skills:

End note program, mendely program, MOI drug design program, Chemdraw program: very good

Windows, Internet, MS Word, MS Power Point : very good.

MS Excel , Access : good.

Language skills:

English:  very good

Membership:

-         Member in The Egyptian General Syndicate of Pharmacists.

-         Trainer in pathway to higher education (research method and how to write proposal )

-         Member in quality team in faculty of pharmacy, Beni-Suef university.

Extra Activities:

    Organization of party,  Presentation, Accessories making , Decoration, Poetry, comedian news

Master Title

Synthesis of Certain Heterocyclic Derivatives of Anticipated Antineoplastic Activity

Master Abstract

Quinazoline derivatives constitute an important class of heterocyclic compounds, many of them possessed a wide range of biological activities as anti-inflammatory, analgesic, antifungal, antibacterial, anticancer and anticonvulsant activities. The presence of natural bioactive products of quinazolines encourage researchers to take quinazoline nucleus as a core for the synthesis of multitude derivatives. Looking at the biological significance of quinazoline nucleus, we aimed to design and synthesize new quinazoline derivatives and screen them for their cytotoxic activity. Moreover, other quinazolines and substituted quinazolinone derivatives are hybridized with different moieties in order to produce compounds with synergistic antitumor activity. On the light of these findings, a new series of 2-substituted quinazolinone, 2,3-disubstituted quinazolinones and 2,4-disubstituted quinazoline derivatives were prepared. This thesis consists of the following parts: 1. Introduction: In this section, literature review presents the various biological and pharmacological activities of quinazolines with a focus on their anticancer activities. Moreover, it displays different methods for their preparation. 2. Aim of the work: It includes the rationale upon which the newly synthesized compounds were designed. 3. Discussion: It deals with the discussion of the various experimental methods, mechanisms and conditions of reactions adopted for the synthesis of the prepared compounds and the confirmation of their structures by brief data of infrared, mass, 1H-NMR and 13C-NMR spectra. 4. Experimental: This part presents the practical procedures used for the synthesis of reported and new intermediates, as well as new final compounds. Also, it includes their microanalytical, physical and spectral data. In order to obtain the new compounds, the following compounds were prepared: ? Reported intermediates (7 compounds): • 2-Methylquinazolin-4(3H)-one II. • 4-Chloro-2-methylquinazoline III. • 2-(Bromomethyl)quinazolin-4(3H)-one VI. • Methyl 2-acetamidobenzoate XIII. • 2-(2-Methyl-4-oxoquinazolin-3(4H)-yl)acetic acid XIV. • 2-(2-Methyl-4-oxoquinazolin-3(4H)-yl)acetyl chloride XV. • 2-(2-Methyl-4-oxoquinazolin-3(4H)-yl)acetohydrazide XVI. ? New intermediates (3 compounds): • 4-((4-Chloroquinazolin-2-yl)methylamino)benzenesulfonamide VIII. • N'-(2-(Bromomethyl)quinazolin-4-yl)benzohydrazide XI. • N'-Formyl-2-(2-methyl-4-oxoquinazolin-3(4H)-yl)acetohydrazide XX. ? New final compounds (25 compounds): • 2-((2-Methylquinazolin-4-yl)amino)propanoic acid IVa. • 2-((2-Methylquinazolin-4-yl)amino)succinic acid IVb. • 2-((2-Methylquinazolin-4-yl)amino)pentanedioic acid IVc. • 2-((2-Methylquinazolin-4-yl)amino)-3-phenylpropanoic acid IVd. • 3,5-Dimethoxy-N'-(2-methylquinazolin-4-yl)benzohydrazide Va. • 3,4,5-Trimethoxy-N'-(2-methylquinazolin-4-yl)benzohydrazide Vb. • N'-(2-Methylquinazolin-4-yl)benzohydrazide Vc. • 4-((4-Oxo-3,4-dihydroquinazolin-2-yl)methylamino)benzenesulfonamide VIIa. • N-(4-((4-Oxo-3,4-dihydroquinazolin-2-yl)methylamino)phenylsulfonyl) acetamide VIIb. • 1-(4-((4-Oxo-3,4-dihydroquinazolin-2-yl)methylamino)phenylsulfonyl) guanidine VIIc. • N-(Isoxazol-3-yl)-4-((4-oxo-3,4-dihydroquinazolin-2-yl)methylamino) benzenesulfonamide VIId. • 4-((4-Oxo-3,4-dihydroquinazolin-2-yl)methylamino)-N-(pyrimidin-2-yl)benzenesulfonamide VIIe. • N-(4,6-Dimethylpyrimidin-2-yl)-4-((4-oxo-3,4-dihydroquinazolin-2-yl)methylamino)benzenesulfonamide VIIf. • 2-((2-(((4-Sulfamoylphenyl)amino)methyl)quinazolin-4-yl)amino)propanoic acid IXa. • 2-((2-(((4-Sulfamoylphenyl)amino)methyl)quinazolin-4-yl)amino)succinic acid IXb. • 2-((2-(((4-Sulfamoylphenyl)amino)methyl)quinazolin-4-yl)amino) pentanedioic acid IXc. • 3-Phenyl-2-((2-(((4-sulfamoylphenyl)amino)methyl)quinazolin-4-yl)amino) propanoic acid IXd. • 4-((4-(2-Isonicotinoylhydrazinyl)quinazolin-2-yl)methylamino) benzenesulfonamide Xa. • 4-((4-(2-Benzoylhydrazinyl)quinazolin-2-yl)methylamino) benzenesulfonamide Xb. • 4-((4-(2-(3,5-Dimethoxybenzoyl)hydrazinyl)quinazolin-2-yl)methylamino) benzenesulfonamide Xc. • 4-((4-(2-(3,4,5-Trimethoxybenzoyl)hydrazinyl)quinazolin-2-yl)methylamino)benzenesulfonamide Xd. • 1-(2-(2-Methyl-4-oxoquinazolin-3(4H)-yl)acetyl)pyrazolidine-3,5-dione XVII. • 3-(2-(3,5-Dimethyl-1H-pyrazol-1-yl)-2-oxoethyl)-2-methylquinazolin-4(3H)-one XVIII. • 2-Methyl-3-(2-(3-methyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl)-2-oxoethyl) quinazolin-4(3H)-one XIX. • 3-((1,3,4-Oxadiazol-2-yl)methyl)-2-methylquinazolin-4(3H)-one XXI. 5. Pharmacological Screening: Antitumor Screening: Fourteen compounds were chosen by U. S. National Cancer Institute for antitumor screening. The results revealed that all tested compounds showed moderate activity against panel of cell line especially CNS and renal cancer, while five compounds Vb, VIIb, IXd, XIX and XXI displayed a significant activity against one cell line. 6. References: This part includes 148 references ranging from 1887 to 2015. 7. Arabic Summary.

PHD Title

not yet

PHD Abstract

not yet